1
|
Tardy-Poncet B, Montmartin A, Chambost H, Lienhart A, Frotscher B, Morange PE, Falaise C, Collange F, Dargaud Y, Toussaint-Hacquard M, Ardillon L, Wibaut B, Jeanpierre E, Nguyen P, Volot F, Tardy B. Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B. Haemophilia 2024; 30:693-701. [PMID: 38650319 DOI: 10.1111/hae.15020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Revised: 04/05/2024] [Accepted: 04/07/2024] [Indexed: 04/25/2024]
Abstract
INTRODUCTION Bleeding severity in severe haemophilic patients, with low thrombin generation (TG) capacity, can vary widely between patients, possibly reflecting differences in tissue factor pathway inhibitor (TFPI) level. AIM To compare free TFPI (fTFPI) levels in patients with severe haemophilia A (sHA) and severe haemophilia B (sHB) and to investigate in these patients as a whole the relationships between bleeding and TG potential, between TG potential and fTFPI level and between fTFPI level and bleeding tendency. METHODS Data on bleeding episodes retrospectively recorded during follow-up visits over 5-10 years were collected and used to calculate the annualised joint bleeding rate (AJBR). fTFPI levels and basal TG parameters were determined in platelet-poor plasma (PPP) and platelet-rich plasma (PRP) using calibrated automated tomography (CAT). RESULTS Mean fTFPI levels did not differ significantly between sHA (n = 34) and sHB (n = 19) patients. Mean values of endogenous thrombin potential (ETP) and thrombin peak (peak) in PPP and PRP were two-fold higher when fTFPI levels < 9.4 versus > 14.3 ng/mL. In patients treated on demand, ETP and peak in PRP were doubled when AJBR was≤ 4.9 $ \le 4.9$ , AJBR being halved in patients with a low fTFPI level (9.4 ng/mL). In patients on factor prophylaxis, no association was found between TG parameters and either fTFPI level or AJBR. CONCLUSION In patients treated on demand, bleeding tendency was influenced by fTFPI levels, which in turn affected basal TG potential. In patients on prophylaxis, bleeding tendency is probably determined primarily by the intensity of this treatment.
Collapse
Affiliation(s)
- Brigitte Tardy-Poncet
- Université Jean Monnet Saint-Étienne, CHUSaint-Étienne, Centre de traitement de l'hémophilie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Saint-Etienne, France
- Inserm CIC 1408, CHU Saint-Étienne, Saint-Etienne, France
| | - Aurélie Montmartin
- Université Jean Monnet Saint-Étienne, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Saint-Etienne, France
| | - Hervé Chambost
- Hôpital Timone, Centre de Traitement de l'Hémophilie, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Anne Lienhart
- Hôpital Cardiologique Louis Pradel, Centre de Référence de l'Hémophilie, Lyon, France
| | - Birgit Frotscher
- Centre de Traitement de l'Hémophilie, CHU de Nancy, Nancy, France
| | - Pierre-Emmanuel Morange
- INSERM, INRAE, C2VN, Laboratoire d'Hématologie, Assistance Publique - Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France
| | - Céline Falaise
- Hôpital Timone, Centre de Traitement de l'Hémophilie, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Fanny Collange
- Inserm CIC 1408, CHU Saint-Étienne, Saint-Etienne, France
| | - Yesim Dargaud
- Hôpital Cardiologique Louis Pradel, Centre de Référence de l'Hémophilie, Lyon, France
- UR 4609 Hémostase & Thrombose, Université Claude Bernard Lyon 1, Lyon, France
| | | | - Laurent Ardillon
- Centre de Traitement de l'Hémophilie, CHU de Tours, Tours, France
| | - Bénédicte Wibaut
- Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles Rares, Centre de Référence Maladie de Willebrand, CHU Lille, Lille, France
| | - Emmanuelle Jeanpierre
- Laboratoire d'Hémostase, Pôle de Biologie Pathologie Génétique Médicale, CHU Lille, Lille, France
| | | | - Fabienne Volot
- Centre de Traitement de l'Hémophilie, CHU Dijon, Dijon, France
| | - Bernard Tardy
- Inserm CIC 1408, CHU Saint-Étienne, Saint-Etienne, France
- Université Jean Monnet Saint-Étienne, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, Saint-Etienne, France
| |
Collapse
|
2
|
Josset L, Leuci A, Janbain M, De-Wreede A, Desage S, Lienhart A, Bin V, Lambert D, Delavenne X, Dargaud Y. Multicenter evaluation of the haemostatic activity of emicizumab in patients with severe haemophilia A. J Thromb Haemost 2024:S1538-7836(24)00181-8. [PMID: 38583717 DOI: 10.1016/j.jtha.2024.03.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Revised: 02/19/2024] [Accepted: 03/25/2024] [Indexed: 04/09/2024]
Abstract
BACKGROUND Emicizumab has been approved for the prophylaxis of patients with hemophilia A with or without inhibitors. However, spontaneous and trauma-induced breakthrough bleeds have been reported in patients on emicizumab prophylaxis and no laboratory assay is validated to evaluate the hemostatic activity of emicizumab . OBJECTIVES The thrombin generation assay (TGA) could be a surrogate marker of the hemostatic efficacy of emicizumab. The correlation between TGA and the methods used to measure emicizumab blood concentration was evaluated in this study. METHODS TGA was modified by the use of a trigger reagent combining a very low concentration of tissue factor (TF) and activated factor XI (FXIa). Emicizumab quantification was performed by three methods, the modified one-step factor VIII (FVIII) assay, and two methods based on liquid chromatography and mass spectrometry (LC-MS). RESULTS Using TF/FXIa-triggered TGA and platelet-poor plasma, a relationship was observed between the area under the thrombin generation curve (ETP) and the clinical response of patients to emicizumab. The ultrastructure of fibrin clots was consistent with ETP results and showed that emicizumab had a hemostatic activity equivalent to 20-30 IU/dL of factor VIII. Finally, pharmacokinetic/pharmacodynamic analyses showed no correlation between ETP and LC-MS nor with modified one-stage FVIII assay, but a statistically significant correlation between the LC-MS methods and the time to peak results of TGA. CONCLUSION Using a modified TGA, this study showed that patients who experienced breakthrough bleeds while on emicizumab had a lower thrombin generating capacity compared to others with good clinical response to emicizumab.
Collapse
Affiliation(s)
- Laurie Josset
- UR4609 - Hémostase et Thrombose, Université Claude Bernard Lyon I, Lyon, France; INSERM, UMR 1059, Dysfonction Vasculaire et de l'Hémostase, Université de Lyon, Saint-Etienne, France
| | - Alexandre Leuci
- UR4609 - Hémostase et Thrombose, Université Claude Bernard Lyon I, Lyon, France
| | - Maissaa Janbain
- Deming Department of Internal Medicine, Section of Hematology and Medical Oncology, Tulane School of Medicine, New Orleans, LA, USA
| | - Anaëlle De-Wreede
- Laboratoire d'Hémostase, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France
| | - Stephanie Desage
- Unite d'Hémostase Clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| | - Anne Lienhart
- Unite d'Hémostase Clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| | - Valérie Bin
- INSERM, UMR 1059, Dysfonction Vasculaire et de l'Hémostase, Université de Lyon, Saint-Etienne, France
| | | | - Xavier Delavenne
- INSERM, UMR 1059, Dysfonction Vasculaire et de l'Hémostase, Université de Lyon, Saint-Etienne, France
| | - Yesim Dargaud
- UR4609 - Hémostase et Thrombose, Université Claude Bernard Lyon I, Lyon, France; Unite d'Hémostase Clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France.
| |
Collapse
|
3
|
Jourdy Y, Chatron N, Frétigny M, Zawadzki C, Lienhart A, Stieltjes N, Rohrlich PS, Thauvin-Robinet C, Volot F, Hamida YF, Hariti G, Leuci A, Dargaud Y, Sanlaville D, Vinciguerra C. Whole F8 gene sequencing identified pathogenic structural variants in the remaining unsolved patients with severe hemophilia A. J Thromb Haemost 2024:S1538-7836(24)00125-9. [PMID: 38484912 DOI: 10.1016/j.jtha.2024.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 02/19/2024] [Accepted: 03/04/2024] [Indexed: 04/01/2024]
Abstract
BACKGROUND No F8 genetic abnormality is detected in approximately 1% to 2% of patients with severe hemophilia A (HA) using conventional genetic approaches. In these patients, deep intronic variation or F8 disrupting genomic rearrangement could be causal. OBJECTIVES The study aimed to identify the causal variation in families with a history of severe HA for whom genetic investigations failed. METHODS We performed whole F8 gene sequencing in 8 propositi. Genomic rearrangements were confirmed by Sanger sequencing of breakpoint junctions and/or quantitative polymerase chain reaction. RESULTS A structural variant disrupting F8 was found in each propositus, so that all the 815 families with a history of severe HA registered in our laboratory received a conclusive genetic diagnosis. These structural variants consisted of 3 balanced inversions, 3 large insertions of gained regions, and 1 retrotransposition of a mobile element. The 3 inversions were 105 Mb, 1.97 Mb, and 0.362 Mb in size. Among the insertions of gained regions, one corresponded to the insertion of a 34 kb gained region from chromosome 6q27 in F8 intron 6, another was the insertion of a 447 kb duplicated region from chromosome 9p22.1 in F8 intron 14, and the last one was the insertion of an Xq28 349 kb gained in F8 intron 5. CONCLUSION All the genetically unsolved cases of severe HA in this cohort were due to structural variants disrupting F8. This study highlights the effectiveness of whole F8 sequencing to improve the molecular diagnosis of HA when the conventional approach fails.
Collapse
Affiliation(s)
- Yohann Jourdy
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'hématologie biologique, Bron, France; Université Claude Bernard Lyon 1, UR4609 Hémostase et thrombose, Lyon, France.
| | - Nicolas Chatron
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de génétique, Bron, France; Université Claude Bernard Lyon 1 - CNRS UMR 5261 -INSERM U1315, Institute NeuroMyoGène, Laboratoire Physiopathologie et Génétique du Neurone et du Muscle, Lyon, France
| | - Mathilde Frétigny
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'hématologie biologique, Bron, France
| | - Christophe Zawadzki
- Pôle de Biologie Pathologie Génétique, Institut d'Hématologie - Transfusion, CHU Lille, Lille, France
| | - Anne Lienhart
- Hospices Civils de Lyon, Lyon Hemophilia Center and Clinical Haemostasis Unit, Bron, France
| | | | | | - Christel Thauvin-Robinet
- Centre de Génétique, Centre de Référence, Déficiences Intellectuelles de Causes Rares, Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France
| | | | | | - Ghania Hariti
- Laboratoire de recherche en hémostase, Université d'Alger 1, Alger, Algérie
| | - Alexandre Leuci
- Université Claude Bernard Lyon 1, UR4609 Hémostase et thrombose, Lyon, France
| | - Yesim Dargaud
- Université Claude Bernard Lyon 1, UR4609 Hémostase et thrombose, Lyon, France; Hospices Civils de Lyon, Lyon Hemophilia Center and Clinical Haemostasis Unit, Bron, France
| | - Damien Sanlaville
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service de génétique, Bron, France; Université Claude Bernard Lyon 1 - CNRS UMR 5261 -INSERM U1315, Institute NeuroMyoGène, Laboratoire Physiopathologie et Génétique du Neurone et du Muscle, Lyon, France
| | - Christine Vinciguerra
- Hospices Civils de Lyon, Groupe Hospitalier Est, Service d'hématologie biologique, Bron, France; Université Claude Bernard Lyon 1, UR4609 Hémostase et thrombose, Lyon, France
| |
Collapse
|
4
|
Désage S, Nougier C, Meunier S, Chamouard V, Jousselme E, Dargaud Y, Lienhart A. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery. Haemophilia 2024; 30:538-544. [PMID: 38149726 DOI: 10.1111/hae.14929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 12/15/2023] [Accepted: 12/15/2023] [Indexed: 12/28/2023]
Abstract
BACKGROUND Efmoroctocog alfa (rFVIIIFc) is an extended half-life FVIII used notably in surgery for patients with haemophilia A. More information is needed of its usage in real-life. METHODS Adult patients with HA followed at the Lyon Comprehensive Hemophilia Care Center who underwent a surgery with rFVIIIFc were included in this retrospective analysis. The pharmacokinetics of rFVIIIFc was assessed by plasma factor VIII clotting activity (FVIII:C) using both one-stage (OSA) and chromogenic substrate (CSA) assays. RESULTS A total of 39 major and 31 minor surgeries were performed in 49 patients treated with rFVIIIFc. The median dose of rFVIIIFc infused before major and minor surgeries respectively was 67.5 ((interquartile range [IQR] 52.6-76.9) and 48.0 (38.5-51.8) IU/kg. For major surgeries, during the first postoperative week, the median residual FVIII:C was 78 (64.5-101.5) IU/dL with OSA and 99 (71-118) IU/dL with CSA (p < .0001). After surgery, rFVIIIFc doses were adjusted according to CSA results. This led to a significant decrease of rFVIIIFc consumption compared to what would have been proposed according to the OSA assay, without unusual bleeding or appearance of inhibitor. Considering the high price of the molecule, this was also associated with a significant cost reduction. CONCLUSION Dose adjustment of rFVIIIFc according to FVIII: C measured by CSA is effective, safe and well tolerated in patients with haemophilia A undergoing invasive surgery.
Collapse
Affiliation(s)
- Stéphanie Désage
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France
| | - Christophe Nougier
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - Sandrine Meunier
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France
| | - Valérie Chamouard
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France
| | - Emilie Jousselme
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - Yesim Dargaud
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France
- UR4609 Hémostase et Thrombose, Faculté de médecine RTH Laënnec, Université Claude Bernard Lyon 1, Lyon, France
| | - Anne Lienhart
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
5
|
Leuci A, Robert M, Josset L, Marano M, Connes P, Désage S, Meunier S, Lienhart A, Dargaud Y. Stromal cell-derived factor 1 alpha (SDF-1alfa) and cartilage oligomeric matrix protein (COMP): Two potential signature biomarkers of radiological detectable hemophilic arthropathy. Int J Rheum Dis 2024; 27:e15061. [PMID: 38465833 DOI: 10.1111/1756-185x.15061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 01/12/2024] [Accepted: 01/19/2024] [Indexed: 03/12/2024]
Abstract
INTRODUCTION Hemophilia is a rare constitutional bleeding disorder due to a deficiency in Factor VIII or Factor IX. Recurrent hemarthroses, one of the major complications of the disease, lead to hemophilic arthropathy, a disabling condition that requires early diagnosis. Traditionally, clinical examination and plain film radiography have been used to diagnose hemophilic arthropathy. Magnetic resonance imaging (MRI) and ultrasound can be more useful for diagnosing soft-tissue changes. However, but each of these methods has limitations and diagnosis of arthropathy can be delayed. AIM The aim of this project was to assess plasmatic biomolecules indicative of osteo-cartilaginous damage in patients with hemophilia with or without known arthropathy, in order to improve the diagnosis of this major complication of the disease. METHODS In this monocentric retrospective study, 40 patients with hemophilia A or B, for whom a plasma sample was available, provided informed consent for further analyses (multiplex immunoassays and ELISA) and collection of relevant clinical information in their medical files. Correlations were sought for between biomarkers of interest and the severity of joint lesions assessed according to Pettersson's radiologic score. RESULTS Two biomarkers were identified, respectively SDF-1α and COMP. Their plasmatic levels were significantly increased in patients with arthropathy compared to controls and patients without arthropathy. These values correlated significantly with the Pettersson score in patients under regular prophylaxis. CONCLUSION Two plasma biomarkers have been identified that could help assess the presence and severity of hemophilic arthropathy.
Collapse
Affiliation(s)
- Alexandre Leuci
- UR4609 Hémostase et Thrombose, Université Claude Bernard Lyon 1, Lyon, France
| | - Mélanie Robert
- UR4609 Hémostase et Thrombose, Université Claude Bernard Lyon 1, Lyon, France
| | - Laurie Josset
- UR4609 Hémostase et Thrombose, Université Claude Bernard Lyon 1, Lyon, France
| | - Muriel Marano
- UR4609 Hémostase et Thrombose, Université Claude Bernard Lyon 1, Lyon, France
| | - Philippe Connes
- Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team « Vascular Biology and Red Blood Cell, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Stéphanie Désage
- Centre de Référence de l'Hémophilie, Unité d'Hémostase Clinique, Hospices Civils de Lyon, Lyon, France
| | - Sandrine Meunier
- Centre de Référence de l'Hémophilie, Unité d'Hémostase Clinique, Hospices Civils de Lyon, Lyon, France
| | - Anne Lienhart
- Centre de Référence de l'Hémophilie, Unité d'Hémostase Clinique, Hospices Civils de Lyon, Lyon, France
| | - Yesim Dargaud
- UR4609 Hémostase et Thrombose, Université Claude Bernard Lyon 1, Lyon, France
- Centre de Référence de l'Hémophilie, Unité d'Hémostase Clinique, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
6
|
Pietu G, Giraud N, Chamouard V, Duport G, Lienhart A, Dargaud Y. Perspectives and perception of haemophilia gene therapy by French patients. Haemophilia 2024; 30:68-74. [PMID: 38058235 DOI: 10.1111/hae.14908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 11/20/2023] [Accepted: 11/27/2023] [Indexed: 12/08/2023]
Abstract
INTRODUCTION AND AIM A national survey was initiated by representatives of French patients with haemophilia (AFH) and the French reference centre for haemophilia, in order to appreciate the awareness and knowledge of these patients regarding haemophilia gene therapy (HGT) and understand better their position about this innovative treatment that will soon become available. RESULTS Of 143 answers received, 137 could be analysed, representing about 3.5% of patients with severe or moderate haemophilia over 16year-old. They were 80.3% with haemophilia A and 19.7 % with haemophilia B, with a severe form of the disease for 80.3 % of them. Curiosity for HGT was formulated by 64.2% of the participants, 33.6 % being interested by this approach as soon as it will be available and 38.7 % preferring to wait until more patients have been treated. Only 3.6 % of the participants would never consider receiving HGT. The level of awareness and knowledge was estimated to be limited by 39.5 % of the patients. More than 60 % of them declared having never or almost never discussed HGT with the team of their haemophilia centre. Before deciding to get HGT, 54.4 % of the participants considered that it will be very important to compare it with their current treatment and 53.7 % would like to be better informed by their care providers. CONCLUSIONS These results highlight the need for training and education for patients, but also for professionals at haemophilia centres, about HGT and the shared decision-making process. Objective, unbiased and transparent information must be available for patients about this very promising therapy which nonetheless carries more uncertainty and unknowns compared to other haemophilia treatments.
Collapse
Affiliation(s)
| | | | - Valérie Chamouard
- Centre de Référence de l'Haémophilie, Unité d'Hémostase Clinique, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France
| | | | - Anne Lienhart
- Centre de Référence de l'Haémophilie, Unité d'Hémostase Clinique, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France
| | - Yesim Dargaud
- Centre de Référence de l'Haémophilie, Unité d'Hémostase Clinique, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
7
|
Favrelle L, Masson JB, Parat S, Carre E, Fessy M, Rioufol C, Lienhart A, Chamouard V, Besse JL. A single-centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost. Haemophilia 2024; 30:204-213. [PMID: 38082545 DOI: 10.1111/hae.14909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 11/21/2023] [Accepted: 11/27/2023] [Indexed: 01/16/2024]
Abstract
INTRODUCTION In patients with haemophilia, repeated bleeding in large joints leads to chronic haemophilic arthropathy, a rare disease that can be managed surgically with ankle arthrodesis or with total ankle replacement (TAR). TAR has been reported to provide good surgical results in the medium/long-term and allow preservation of joint mobility but the medical therapeutic management of the patients has not been described. AIM To describe the medical therapeutic management of TAR. METHODS All patients with haemophilia A/B, with haemophilic ankle arthropathy, and who underwent TAR between April 2006 and October 2019 were retrospectively included. Factor consumption, perioperative and early complications, volume of blood lost, and orthopaedic data were collected. RESULTS A total of 25 patients underwent 29 TAR (mean age was 44.7 years [range: 26-65]). In the 17 patients with HA without history of anti-FVIII inhibitor, the mean ± SD consumption the day of surgery was 116 ± 16 UI/kg when clotting factors were administered by continuous infusion, 106 ± 13 UI/kg when SHL factors were administered by bolus infusion, and 75 ± 22 UI/kg when EHL factors were administered by bolus infusion. During hospitalisation, the mean factor cost was €38,073 (83.7% of the total cost of surgery). Mean blood loss was significantly lower in patients treated with tranexamic acid (164 mL, range: 40-300) than in those not (300 mL, range: 70-800; p = .01). Six patients had haematoma. The 10-year survival free of any prosthesis removal/arthrodesis was estimated to be 92.2% (95% CI [83; 100]). CONCLUSION The medical therapeutic management of TAR is complex, carried out by a multidisciplinary team but effective in avoiding the occurrence of complications.
Collapse
Affiliation(s)
- Louise Favrelle
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de pharmacie, Pierre-Bénite, France
| | - Jean-Baptiste Masson
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Chirurgie Orthopédique et Traumatologique, Pierre-Bénite, France
| | - Stéphanie Parat
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de pharmacie, Pierre-Bénite, France
| | - Emmanuelle Carre
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de pharmacie, Pierre-Bénite, France
| | - Michel Fessy
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Chirurgie Orthopédique et Traumatologique, Pierre-Bénite, France
- Université Lyon 1, IFSTTAR, LBMC UMR-T 9406 - Laboratoire de Biomécanique et Mécanique des Chocs, Bron, France
| | - Catherine Rioufol
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de pharmacie, Pierre-Bénite, France
| | - Anne Lienhart
- Hospices Civils de Lyon, Groupement Hospitalier Est, Service d'Hémostase clinique, Bron, France
| | - Valérie Chamouard
- Hospices Civils de Lyon, Groupement Hospitalier Est, Service d'Hémostase clinique, Bron, France
- Hospices Civils de Lyon, Groupement Hospitalier Est, Service de pharmacie, Bron, France
| | - Jean-Luc Besse
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service de Chirurgie Orthopédique et Traumatologique, Pierre-Bénite, France
- Université Lyon 1, IFSTTAR, LBMC UMR-T 9406 - Laboratoire de Biomécanique et Mécanique des Chocs, Bron, France
| |
Collapse
|
8
|
Nguyen NAT, Auquier P, Beltran Anzola A, d'Oiron R, Biron-Andréani C, Lienhart A, Rauch A, Baumstarck K, Boucekine M, Milien V, Rosso-Delsemme N, Tabele C, Giraud N, Sannié T, Chambost H, Resseguier N. Occupational integration of adults with severe haemophilia (INTHEMO): A study based on the FranceCoag registry. Haemophilia 2022; 28:962-976. [PMID: 35858674 DOI: 10.1111/hae.14620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 06/13/2022] [Accepted: 06/22/2022] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Health of people with severe haemophilia (PwSH) improves thanks to the advancements in haemophilia care, giving them more opportunities in occupational integration. However, there is little literature on the occupational integration of PwSH. OBJECTIVES The main objective of our study was to assess the occupational integration of PwSH and to compare it with that of the general population. The secondary objective was to study the association between individual characteristics (sociodemographic, clinical and psycho-behavioural) and occupational integration of PwSH. METHODS A multicentre, non-interventional, cross-sectional study was conducted in 2018-2020 on PwSH, aged over 18 and under 65 years and included in the FranceCoag registry. Measurements included indicators of occupational integration, sociodemographic, clinical and psycho-behavioural characteristics. The indicators of occupational integration were compared with those of the general population, using indirect standardization. The data of the general population were available from the National Institute of Statistics and Economic Studies (INSEE). Determinants of occupational integration were explored using structural equation modelling. RESULTS Of 1262 eligible people, 588 were included. PwSH had a lower employment rate than the general population (standardized ratio, .85; 95% CI, .77-.94). There were more PwSH at tertiary education level than expected (standardized ratio, 1.38; 95% CI, 1.17-1.61). HIV infection, poor physical health and mental health concerns were associated with a higher risk of unemployment in PwSH. CONCLUSION Employment rate of PwSH is lower than that of the general population despite their higher education level. Target interventions focusing on determinants of difficult occupational integration could be helpful for PwSH.
Collapse
Affiliation(s)
- Ngoc Anh Thu Nguyen
- CEReSS - Health Services and Quality of Life Research, Aix Marseille University, Marseille, France.,Methodological Support Unit for Clinical and Epidemiological Research, University Hospital of Marseille (APHM), Marseille, France
| | - Pascal Auquier
- CEReSS - Health Services and Quality of Life Research, Aix Marseille University, Marseille, France.,Methodological Support Unit for Clinical and Epidemiological Research, University Hospital of Marseille (APHM), Marseille, France.,FranceCoag Network, Marseille, France
| | - Any Beltran Anzola
- CEReSS - Health Services and Quality of Life Research, Aix Marseille University, Marseille, France.,Methodological Support Unit for Clinical and Epidemiological Research, University Hospital of Marseille (APHM), Marseille, France
| | - Roseline d'Oiron
- Haemophilia Treatment Centre, Bicêtre Hospital, University Hospital of Paris (APHP), Kremlin-Bicêtre, France
| | | | - Anne Lienhart
- Haemophilia Treatment Centre, Hospital Edouard Herriot, University Hospital of Lyon, Bron, France
| | - Antoine Rauch
- Haemophilia Treatment Centre, University Regional Hospital of Lille, Lille, France
| | - Karine Baumstarck
- CEReSS - Health Services and Quality of Life Research, Aix Marseille University, Marseille, France.,Methodological Support Unit for Clinical and Epidemiological Research, University Hospital of Marseille (APHM), Marseille, France.,FranceCoag Network, Marseille, France
| | - Mohamed Boucekine
- CEReSS - Health Services and Quality of Life Research, Aix Marseille University, Marseille, France.,Methodological Support Unit for Clinical and Epidemiological Research, University Hospital of Marseille (APHM), Marseille, France.,FranceCoag Network, Marseille, France
| | - Vanessa Milien
- FranceCoag Network, Marseille, France.,Haemophilia Treatment Centre, Timone Hospital, University Hospital of Marseille (APHM), Marseille, France
| | - Natacha Rosso-Delsemme
- Haemophilia Treatment Centre, Timone Hospital, University Hospital of Marseille (APHM), Marseille, France
| | - Clemence Tabele
- CEReSS - Health Services and Quality of Life Research, Aix Marseille University, Marseille, France.,FranceCoag Network, Marseille, France
| | - Nicolas Giraud
- Association française des hémophiles (AFH), Paris, France
| | - Thomas Sannié
- Association française des hémophiles (AFH), Paris, France
| | - Hervé Chambost
- FranceCoag Network, Marseille, France.,Haemophilia Treatment Centre, Timone Hospital, University Hospital of Marseille (APHM), Marseille, France
| | - Noémie Resseguier
- CEReSS - Health Services and Quality of Life Research, Aix Marseille University, Marseille, France.,Methodological Support Unit for Clinical and Epidemiological Research, University Hospital of Marseille (APHM), Marseille, France
| | | |
Collapse
|
9
|
Désage S, Dargaud Y, Meunier S, Le Quellec S, Lienhart A, Negrier C, Nougier C, Rugeri L. Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single-centre study. Haemophilia 2022; 28:301-307. [PMID: 35122661 DOI: 10.1111/hae.14506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2021] [Revised: 01/12/2022] [Accepted: 01/26/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND In patients with FXI deficiency, the risk of surgery-related bleeding is poorly correlated with plasma FXI activity (FXI:C); the latter can therefore not be used as a reliable predictor of bleeding in surgeries. OBJECTIVES The aim of this retrospective study was to determine whether thrombin generation assay (TGA) could be used to evaluate the risk of surgery-related bleeding in FXI-deficient patients. TGA parameters were compared to FXI:C values, haemostatic treatments and surgical outcomes. PATIENTS All patients followed at the haemophilia treatment care centre (Lyon, France) with a FXI:C < 50IU/dL, and for whom a baseline TGA was performed between January 2014 and December 2019, were included. RESULTS Among the 175 surgeries reported herein in 49 patients, FXI concentrates were used for 11 (6%) surgeries and fresh frozen plasma was used for five (3%) surgeries; these surgeries were performed in patients with two or three impaired TGA parameters. No haemostatic treatment was prescribed for 119 (68%) surgeries. A surgery-related bleeding occurred in 12 patients during 21 (12%) surgeries. Thrombin generation was significantly reduced or delayed in patients who reported surgery related-bleeding. Among the 34 (68%) surgeries performed without haemostatic treatment in patients with three impaired TGA parameters, a surgery-related bleeding was reported in 44% of cases (15 surgeries out of 34). CONCLUSION The present study confirmed that TGA is an interesting laboratory test in FXI deficiency, for determining the bleeding risk and guiding the haemostatic management of surgeries, while taking into account the surgical bleeding risk and the history of bleeding.
Collapse
Affiliation(s)
- Stéphanie Désage
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France.,Laboratoire d'hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - Yesim Dargaud
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France.,Laboratoire d'hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.,Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, Lyon, France
| | - Sandrine Meunier
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France
| | - Sandra Le Quellec
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France.,Laboratoire d'hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.,Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, Lyon, France
| | - Anne Lienhart
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France
| | - Claude Negrier
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France.,Laboratoire d'hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.,Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, Lyon, France
| | - Christophe Nougier
- Laboratoire d'hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - Lucia Rugeri
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France
| |
Collapse
|
10
|
Pitance V, Désage S, Lienhart A, Meunier S, Chamouard V. Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa. Haemophilia 2021; 27:e368-e375. [PMID: 33780111 DOI: 10.1111/hae.14301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 02/16/2021] [Accepted: 03/15/2021] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Lightening the injection burden is commonly believed to improve prophylaxis adherence. Efmoroctocog alfa (rFVIIIFc) is the first recombinant FVIII-Fc fusion protein available in France. This clotting factor with an extended half-life could thus improve medication adherence. AIM The study primarily aimed to assess the real-life impact on prophylaxis adherence of haemophilia A patients, when switching from a standard to an extended half-life FVIII. METHODS This study was an observational, monocentre, non-interventional study aiming at assessing haemophilia A patients' real-life adherence during the first-year post-rFVIIIFc prophylaxis initiation. Medication adherence was assessed using two methods: the medication possession ratio (MPR), which is based on the hospital pharmacy dispensing data, and self-reported VERITAS-Pro® questionnaire. Patients on rFVIIIFc prophylaxis for at least 12 months, following a 12-month standard FVIII prophylaxis, were eligible for inclusion. RESULTS In 2019, 47 male patients were undergoing rFVIIIFc prophylaxis in our Hemophilia Center, among which 36 meeting the inclusion criteria. Switching from standard to extended half-life FVIII prophylaxis resulted in increased mean dosing, while the mean number of weekly prophylactic injections (2.6 ± 0.5 vs 1.8 ± 0.3) decreased. Following rFVIIIFc initiation, a non-significant increase in median MPR occurred and the self-reported VERITAS-Pro® questionnaire demonstrated improved adherence to rFVIIIFc prophylaxis. Comparing adherent and non-adherent patients revealed age as the only factor likely to impact adherence (p = .07). CONCLUSION Our patient cohort exhibited high adherence levels before and after FVIII switching, based on MPR and VERITAS-Pro® questionnaire. The latter is likely a useful tool to quantity prophylaxis adherence from a patient's perspective in daily use.
Collapse
Affiliation(s)
- Victoire Pitance
- Hospices Civils de Lyon, Unité Hémostase Clinique, Hôpital Louis Pradel, Bron, France
| | - Stéphanie Désage
- Hospices Civils de Lyon, Unité Hémostase Clinique, Hôpital Louis Pradel, Bron, France
| | - Anne Lienhart
- Hospices Civils de Lyon, Unité Hémostase Clinique, Hôpital Louis Pradel, Bron, France
| | - Sandrine Meunier
- Hospices Civils de Lyon, Unité Hémostase Clinique, Hôpital Louis Pradel, Bron, France
| | - Valérie Chamouard
- Hospices Civils de Lyon, Unité Hémostase Clinique, Hôpital Louis Pradel, Bron, France.,Hospices Civils de Lyon, Pharmacie, Hôpital Louis Pradel, Bron, France
| |
Collapse
|
11
|
Mangin MA, Lienhart A, Gouraud A, Roux S, Hodique F, Jouen F, Balme B, Dalle S, Debarbieux S. Onset of acquired haemophilia A after omalizumab treatment in severe bullous pemphigoid - a report on two cases successfully treated with mycophenolate mofetil. Ann Dermatol Venereol 2021; 148:57-59. [PMID: 33461795 DOI: 10.1016/j.annder.2020.09.577] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 08/24/2020] [Accepted: 09/30/2020] [Indexed: 10/22/2022]
Affiliation(s)
- M-A Mangin
- Service de dermatologie, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France.
| | - A Lienhart
- Hospices civils de Lyon, groupement hospitalier Est, centre régional de traitement de l'Hémophilie, 69500 Bron cedex, France
| | - A Gouraud
- Pharmacovigilance, hospices civils de Lyon, centre hospitalier Lyon Sud, 69495 Pierre-Bénite cedex, France
| | - S Roux
- Service de maladies infectieuses et tropicales, hospices civils de Lyon, hôpital de la Croix Rousse, 69004 Lyon, France
| | - F Hodique
- Service de maladies infectieuses et tropicales, hospices civils de Lyon, hôpital de la Croix Rousse, 69004 Lyon, France
| | - F Jouen
- Biologie médicale, centre hospitalier de Rouen, hôpital Charles-Nicole, 76031 Rouen cedex, France
| | - B Balme
- Service d'anatomopathologie, hospices civils de Lyon, centre hospitalier Lyon Sud, 69495 Pierre-Bénite cedex, France
| | - S Dalle
- Service de dermatologie, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France
| | - S Debarbieux
- Service de dermatologie, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France
| |
Collapse
|
12
|
Row C, Chamouni P, Berger C, Lienhart A, Meunier S, Fretigny M, Dalibard V, Viprey M, Chambost H, Barbay V, Bovet J. Abnormal bleeding phenotype for mild haemophilia B patients with the p.Ile112Thr variation on the gene for factor IX. Haemophilia 2020; 27:e462-e465. [PMID: 32996663 DOI: 10.1111/hae.14146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 07/16/2020] [Accepted: 08/16/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Céline Row
- Thrombosis and Hemostasis Unit, University Hospital of Dijon, Dijon, France
| | - Pierre Chamouni
- Hemophilia Treatment Center, University Hospital of Rouen, Rouen, France
| | - Claire Berger
- Hemophilia Treatment Center, Pediatric Hematology department, University Hospital of Saint Etienne, Saint Etienne, France
| | - Anne Lienhart
- Hospices Civils de Lyon, French Reference Centre for Hemophilia, University Hospital of Lyon, France
| | - Sandrine Meunier
- Hospices Civils de Lyon, French Reference Centre for Hemophilia, University Hospital of Lyon, France
| | | | - Vincent Dalibard
- Lille CHRU, Hemophilia Treatment Center, Hematology and Transfusion, Lille, France.,APHM, FranceCoag, Research Department, Marseille, France
| | - Marie Viprey
- APHM, FranceCoag, Research Department, Marseille, France.,Aix-Marseille Univ, EA 3279 CEReSS-Health Service Research and Quality of Life Center, Marseille, France
| | - Hervé Chambost
- APHM, Hemophilia Treatment Center, La Timone Hospital and Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France
| | - Virginie Barbay
- Hemophilia Treatment Center, University Hospital of Rouen, Rouen, France
| | - Julien Bovet
- Thrombosis and Hemostasis Unit, University Hospital of Dijon, Dijon, France
| |
Collapse
|
13
|
Drillaud N, Babuty A, Rugeri L, Fouassier M, Lienhart A, Béné M, Lefranc C, Ternisien C, Chamouard V, Sigaud M, Pennetier M, Trossaërt M, Meunier S. Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: Two French centres' real‐life experience. Haemophilia 2020; 26:e349-e352. [DOI: 10.1111/hae.14132] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 07/30/2020] [Accepted: 07/30/2020] [Indexed: 11/28/2022]
Affiliation(s)
| | - Antoine Babuty
- Haemophilia Treatment Center University Hospital Nantes France
| | - Lucia Rugeri
- Haemophilia Treatment Center University Hospital Lyon France
| | - Marc Fouassier
- Haemophilia Treatment Center University Hospital Nantes France
| | - Anne Lienhart
- Haemophilia Treatment Center University Hospital Lyon France
| | - Marie‐C Béné
- Haemophilia Treatment Center University Hospital Nantes France
| | - Carole Lefranc
- Haemophilia Treatment Center University Hospital Lyon France
| | | | | | - Marianne Sigaud
- Haemophilia Treatment Center University Hospital Nantes France
| | | | - Marc Trossaërt
- Haemophilia Treatment Center University Hospital Nantes France
| | | |
Collapse
|
14
|
Dericquebourg A, Jourdy Y, Fretigny M, Lienhart A, Claeyssens S, Ternisien C, Boisseau P, Rohrlich P, Négrier C, Vinciguerra C. Identification of new
F8
deep intronic variations in patients with haemophilia A. Haemophilia 2020; 26:847-854. [DOI: 10.1111/hae.14134] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 07/28/2020] [Accepted: 08/04/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Amy Dericquebourg
- Service d’Hématologie BiologiqueCentre de Biologie et Pathologie Est Hospices Civils de Lyon France
- EA 4609 Hémostase et cancerUniversité Claude Bernard Lyon 1Univ. Lyon France
| | - Yohann Jourdy
- Service d’Hématologie BiologiqueCentre de Biologie et Pathologie Est Hospices Civils de Lyon France
- EA 4609 Hémostase et cancerUniversité Claude Bernard Lyon 1Univ. Lyon France
| | - Mathilde Fretigny
- Service d’Hématologie BiologiqueCentre de Biologie et Pathologie Est Hospices Civils de Lyon France
| | - Anne Lienhart
- Unité d'Hémostase CliniqueHôpital Cardiologique Louis Pradel Lyon, Hospices Civils de Lyon France
| | - Ségolène Claeyssens
- Centre de Ressources et de Compétences Maladies Hémorragiques Constitutionnelles Centre Hospitalier Universitaire de Toulouse‐Purpan Toulouse France
| | | | | | | | - Claude Négrier
- Service d’Hématologie BiologiqueCentre de Biologie et Pathologie Est Hospices Civils de Lyon France
- EA 4609 Hémostase et cancerUniversité Claude Bernard Lyon 1Univ. Lyon France
- Unité d'Hémostase CliniqueHôpital Cardiologique Louis Pradel Lyon, Hospices Civils de Lyon France
| | - Christine Vinciguerra
- Service d’Hématologie BiologiqueCentre de Biologie et Pathologie Est Hospices Civils de Lyon France
- EA 4609 Hémostase et cancerUniversité Claude Bernard Lyon 1Univ. Lyon France
| |
Collapse
|
15
|
Bel F, Meunier S, Lienhart A, Revy A, Chamouard V. Evolution of clotting factor concentrates prescriptions and impact of recommendations of prophylaxis in children with haemophilia. Therapie 2020; 76:23-29. [PMID: 32711847 DOI: 10.1016/j.therap.2020.06.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 04/09/2020] [Accepted: 06/26/2020] [Indexed: 10/23/2022]
Abstract
Prophylaxis treatment is considered as the reference approach for children with severe haemophilia A or B. However, no consensus about the best prophylaxis protocol has yet been identified in term of dosage and timing of infusions. Guidelines were drawn up in France in the early 2000s by an expert group. The objective of this 16-year study (2001 to 2016) was to describe the clotting factor concentrates (CFCs) use in haemophiac outpatients. This is a retrospective monocentric study. Pharmaceutical and clinical data were captured using medical records. Main outcome measures are CFCs use and clinical data in paediatrics. Eighty haemophiliacs A or B under 12 years old with a factor level less than 2% were included (74% of HA), from pharmaceutical outpatient data. Global use of CFCs followed the evolution of the patients' number and regimen type introduced: increase of prophylaxis and decrease of on demand regimen. The average age at the prophylaxis introduction is significantly different according to the birth year. Prophylaxis introduction was made earlier with an increase of prophylactic regimen joined to an increase of CFCs use. The significant reduction of haemarthrosis in our cohort can be linked to a first infusion age and a prophylaxis introduction much earlier.
Collapse
Affiliation(s)
- Florianne Bel
- Pharmacie, groupement hospitalier Est, Hospices civils de Lyon, 61, boulevard Pinel, 69500 Bron, France
| | - Sandrine Meunier
- Centre régional de traitement de l'hémophilie, groupement hospitalier Est, Hospices civils de Lyon, 69500 Bron, France
| | - Anne Lienhart
- Centre régional de traitement de l'hémophilie, groupement hospitalier Est, Hospices civils de Lyon, 69500 Bron, France
| | - Alban Revy
- Pharmacie, groupement hospitalier Est, Hospices civils de Lyon, 61, boulevard Pinel, 69500 Bron, France
| | - Valérie Chamouard
- Pharmacie, groupement hospitalier Est, Hospices civils de Lyon, 61, boulevard Pinel, 69500 Bron, France; Centre régional de traitement de l'hémophilie, groupement hospitalier Est, Hospices civils de Lyon, 69500 Bron, France.
| |
Collapse
|
16
|
Négrier C, Chamouard V, Lienhart A, Nougier C, Fleury R. A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini-pump system. Haemophilia 2020; 25:1020-1027. [PMID: 31769912 DOI: 10.1111/hae.13863] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 09/09/2019] [Accepted: 10/02/2019] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Recombinant FVIIa (rFVIIa) is widely used to manage bleeding risk during and after surgery in patients with haemophilia complicated by inhibitors. In the postoperative period, rFVIIa must be delivered frequently and regularly to maintain haemostasis, considering its short half-life. Preparation and manual administration of bolus doses of rFVIIa at regular intervals may place a strain on available nursing resources. A programmable mini-pump may offer an approach to facilitate regular administration of bolus doses of rFVIIa at specified intervals. AIM To investigate if a mini-pump is a practical and effective way to deliver rFVIIa in the postoperative period. METHODS It was first necessary to establish that rFVIIa remains stable and sterile in the mini-pump reservoir for an extended period. Four days after loading the mini-pump under sterile conditions no evidence of bacterial or fungal growth was observed and in vitro procoagulant activity of rFVIIa remained stable. The mini-pump was used to deliver rFVIIa as bolus doses to two patients with inhibitors who had undergone surgery. Nurses were asked to report their satisfaction with the use of the mini-pump using a specific questionnaire. RESULTS Haemostasis was evaluated as excellent in both cases; nurses were satisfied with use of the mini-pump. CONCLUSION This pilot study shows that intermittent delivery of rFVIIa at fixed intervals using an automated mini-pump offers accurate and reliable administration in the postoperative setting. This approach may reduce burden on nursing staff, potentially minimize the risk of human error and avoid delay in administration of rFVIIa.
Collapse
Affiliation(s)
- Claude Négrier
- Unité d'Hémostase Clinique, Centre Régional de Traitement de l'Hémophilie, Hôpital Louis Pradel, Université Lyon 1, Lyon, France
| | - Valerie Chamouard
- Unité d'Hémostase Clinique, Centre Régional de Traitement de l'Hémophilie, Hôpital Louis Pradel, Université Lyon 1, Lyon, France
| | - Anne Lienhart
- Unité d'Hémostase Clinique, Centre Régional de Traitement de l'Hémophilie, Hôpital Louis Pradel, Université Lyon 1, Lyon, France
| | - Christophe Nougier
- Laboratoire d'Hématologie, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
| | - Raphael Fleury
- Unité d'Hémostase Clinique, Centre Régional de Traitement de l'Hémophilie, Hôpital Louis Pradel, Université Lyon 1, Lyon, France
| |
Collapse
|
17
|
Delavenne X, Ollier E, Lienhart A, Dargaud Y. A new paradigm for personalized prophylaxis for patients with severe haemophilia A. Haemophilia 2020; 26:228-235. [PMID: 32100950 PMCID: PMC7154752 DOI: 10.1111/hae.13935] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 11/12/2019] [Accepted: 01/17/2020] [Indexed: 02/04/2023]
Abstract
AIM For patients with severe haemophilia A, guidelines recommend prophylactic treatment with FVIII, with dose calculations targeting a predetermined FVIII trough level. However, this pharmacokinetic (PK) approach is suboptimal, with some patients experiencing breakthrough bleeds. We aimed to improve FVIII dosing by incorporating the thrombin generation assay, a global haemostasis assay whose main pharmacodynamic (PD) parameter, endogenous thrombin potential (ETP), predicts spontaneous bleeding risk. METHODS We performed post hoc combined PK-PD modelling using data from 66 adults who received human-cl rhFVIII (Nuwiq® , Octapharma AG) in a phase IIIb study. Time-to-event analyses simulated the probability of spontaneous bleeding for different FVIII exposures and baseline ETPs. RESULTS Ninety-one spontaneous bleeds occurred in 20/66 patients. The relationship between FVIII:C and ETP was non-linear, and the sigmoid Emax model adequately described the data. Individual PK-PD Bayesian estimation significantly improved predictive performance. Simulations showed that the mean spontaneous annual bleeding rate decreased with increasing baseline ETP or dosing: with ETP values of 200, 400 and 600 (nmol/L)·min annual bleeding rates were 2.36, 1.25 and 0.66, respectively, on 40 IU/kg human-cl rhFVIII every 3 days; and annual bleeding rates were 2.09, 1.10, and 0.60, respectively, on 60 IU/kg every 3 days. CONCLUSION Prophylactic FVIII dosing is more clinically meaningful when incorporating ETP alongside FVIII level. For the first time, FVIII dosing can be personalized with the aim of eliminating spontaneous breakthrough bleeds.
Collapse
Affiliation(s)
- Xavier Delavenne
- Institut national de la santé et de la recherche médicale (Inserm), UMR 1059, Dysfonction Vasculaire et de l'Hémostase, Université de Lyon, Saint Etienne, France
| | - Edouard Ollier
- Institut national de la santé et de la recherche médicale (Inserm), UMR 1059, Dysfonction Vasculaire et de l'Hémostase, Université de Lyon, Saint Etienne, France
| | - Anne Lienhart
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Université Lyon 1, Lyon, France
| | - Yesim Dargaud
- Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Université Lyon 1, Lyon, France
| |
Collapse
|
18
|
Mangin M, Lienhart A, Gouraud A, Roux S, Hodique F, Balme B, Jouen F, Dalle S, Debarbieux S. Deux cas d’hémophilie A acquise associée à une pemphigoïde bulleuse traitée par omalizumab : coïncidence ou effet secondaire ? Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Désage S, Le Quellec S, Karlin L, Lienhart A, Meunier S, Rugeri L. A Prolonged Treatment Response in Acquired Von Willebrand Syndrome. Hamostaseologie 2019; 39:409-412. [PMID: 31546261 DOI: 10.1055/s-0039-1696960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder. We report herein a case of AVWS due to a monoclonal gammopathy of undetermined significance, in which a transient but prolonged response to a treatment by intravenous immunoglobulin (IVIG) was observed. The diagnosis was fortuitously made in a preoperative setting for neurosurgery, after biological exploration of an isolated prolonged activated partial thromboplastin time. AVWS was confirmed by an accelerated clearance of an infused plasma-derived von Willebrand factor (VWF) concentrate. High doses of IVIG were used to perform the neurosurgery. Fifty-four days after IVIG, the patient was still responding to treatment with normal levels of factor VIII and VWF.
Collapse
Affiliation(s)
- Stéphanie Désage
- Laboratoire d'hématologie, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - Sandra Le Quellec
- Service d'hémostase clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| | - Lionel Karlin
- Service d'hématologie clinique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Anne Lienhart
- Service d'hémostase clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| | - Sandrine Meunier
- Service d'hémostase clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| | - Lucia Rugeri
- Service d'hémostase clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
20
|
Désage S, Jousselme E, Le Quellec S, Lienhart A, Nougier C, Dargaud Y, Jourdy Y. The potential value of thrombin generation assay in the diagnosis of FV inhibitors. Int J Lab Hematol 2019; 41:e117-e120. [PMID: 30953579 DOI: 10.1111/ijlh.13027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 03/14/2019] [Accepted: 03/15/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Stéphanie Désage
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.,EA 4609 Hémostase et Cancer, Université Claude Bernard Lyon 1, University Lyon, Lyon, France
| | - Emilie Jousselme
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - Sandra Le Quellec
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.,EA 4609 Hémostase et Cancer, Université Claude Bernard Lyon 1, University Lyon, Lyon, France.,Service d'hémostase Clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| | - Anne Lienhart
- EA 4609 Hémostase et Cancer, Université Claude Bernard Lyon 1, University Lyon, Lyon, France.,Service d'hémostase Clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| | - Christophe Nougier
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France
| | - Yesim Dargaud
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.,EA 4609 Hémostase et Cancer, Université Claude Bernard Lyon 1, University Lyon, Lyon, France.,Service d'hémostase Clinique, Hôpital Cardiologique, Hospices Civils de Lyon, Lyon, France
| | - Yohann Jourdy
- Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.,EA 4609 Hémostase et Cancer, Université Claude Bernard Lyon 1, University Lyon, Lyon, France
| |
Collapse
|
21
|
Chelle P, Montmartin A, Damien P, Piot M, Cournil M, Lienhart A, Genre‐Volot F, Chambost H, Morin C, Tardy‐Poncet B. Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients. Haemophilia 2019; 25:343-348. [DOI: 10.1111/hae.13679] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Revised: 12/14/2018] [Accepted: 12/14/2018] [Indexed: 11/30/2022]
Affiliation(s)
- Pierre Chelle
- CIS‐EMSE, SAINBIOSE Ecole Nationale Supérieure des Mines de Saint‐Etienne Saint Etienne France
- INSERM, U1059, SAINBIOSE Université de Lyon, UJM‐Saint‐Etienne Saint‐Etienne France
| | - Aurélie Montmartin
- INSERM, U1059, SAINBIOSE Université de Lyon, UJM‐Saint‐Etienne Saint‐Etienne France
| | - Pauline Damien
- INSERM, CIC 1408, FCRIN‐INNOVTE CHU Saint‐Etienne Saint‐Etienne France
| | - Michèle Piot
- INSERM, U1059, SAINBIOSE Université de Lyon, UJM‐Saint‐Etienne Saint‐Etienne France
| | - Michel Cournil
- CIS‐EMSE, SAINBIOSE Ecole Nationale Supérieure des Mines de Saint‐Etienne Saint Etienne France
- INSERM, U1059, SAINBIOSE Université de Lyon, UJM‐Saint‐Etienne Saint‐Etienne France
| | - Anne Lienhart
- Centre de référence et de traitement de l’hémophilie Hopital Cardiologique Louis Pradel Lyon France
| | | | - Hervé Chambost
- Centre de traitement de l’hémophilie Hôpital d’enfants La Timone Marseille France
| | - Claire Morin
- CIS‐EMSE, SAINBIOSE Ecole Nationale Supérieure des Mines de Saint‐Etienne Saint Etienne France
| | - Brigitte Tardy‐Poncet
- INSERM, U1059, SAINBIOSE Université de Lyon, UJM‐Saint‐Etienne Saint‐Etienne France
- INSERM, CIC 1408, FCRIN‐INNOVTE CHU Saint‐Etienne Saint‐Etienne France
- Centre de traitement de l’hémophilie CHU Saint‐Etienne Saint‐Etienne France
| |
Collapse
|
22
|
Xu Z, Dargaud Y, Chamouard V, Le Quellec S, Lienhart A, Meunier S, Rugeri L. A single-centre study of management of pregnant women with von Willebrand disease. Haemophilia 2018; 25:e54-e57. [DOI: 10.1111/hae.13653] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 11/08/2018] [Accepted: 11/09/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Zizhen Xu
- Hospices Civils de Lyon, Unité d'Hémostase Clinique/Centre Régional de Traitement de l'Hémophilie; Hôpital Louis Pradel; Bron Cedex France
- Department of Laboratory Medicine, Ruijin Hospital; Shanghai Jiao Tong University School of Medicine; Shanghai China
| | - Yesim Dargaud
- Hospices Civils de Lyon, Unité d'Hémostase Clinique/Centre Régional de Traitement de l'Hémophilie; Hôpital Louis Pradel; Bron Cedex France
| | - Valérie Chamouard
- Hospices Civils de Lyon, Unité d'Hémostase Clinique/Centre Régional de Traitement de l'Hémophilie; Hôpital Louis Pradel; Bron Cedex France
| | - Sandra Le Quellec
- Hospices Civils de Lyon, Unité d'Hémostase Clinique/Centre Régional de Traitement de l'Hémophilie; Hôpital Louis Pradel; Bron Cedex France
| | - Anne Lienhart
- Hospices Civils de Lyon, Unité d'Hémostase Clinique/Centre Régional de Traitement de l'Hémophilie; Hôpital Louis Pradel; Bron Cedex France
| | - Sandrine Meunier
- Hospices Civils de Lyon, Unité d'Hémostase Clinique/Centre Régional de Traitement de l'Hémophilie; Hôpital Louis Pradel; Bron Cedex France
| | - Lucia Rugeri
- Hospices Civils de Lyon, Unité d'Hémostase Clinique/Centre Régional de Traitement de l'Hémophilie; Hôpital Louis Pradel; Bron Cedex France
| |
Collapse
|
23
|
Desjonqueres A, Guillet B, Beurrier P, Pan‐Petesch B, Ardillon L, Pineau‐Vincent F, Sigaud M, Fouassier M, Ternisien C, Gillet B, Béné M, Horvais V, Lienhart A, Trossaërt M. Bleeding risk for patients with haemophilia under antithrombotic therapy. Results of the French multicentric study
ERHEA. Br J Haematol 2018; 185:764-767. [DOI: 10.1111/bjh.15606] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Lienhart A, Meunier S. [Diagnostic strategy in patient with abnormality of the coagulation balance]. Rev Prat 2018; 68:e320. [PMID: 30869469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Anne Lienhart
- Service hémostase clinique ; centre régional de traitement des hémophiles (CRTH) ; centre de référence des maladies hémorragiques constitutionnelles (CRMH) hors maladie de von Willebrand ; Groupement hospitalier Est ; Hôpital cardiologique, 69000 Bron, France
| | - Sandrine Meunier
- Service hémostase clinique ; centre régional de traitement des hémophiles (CRTH) ; centre de référence des maladies hémorragiques constitutionnelles (CRMH) hors maladie de von Willebrand ; Groupement hospitalier Est ; Hôpital cardiologique, 69000 Bron, France
| |
Collapse
|
25
|
Lienhart A, Meunier S. [Hemorrhagic syndrome with hematologic origin]. Rev Prat 2018; 68:e311-e319. [PMID: 30869468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Anne Lienhart
- Service hémostase clinique ; centre régional de traitement des hémophiles (CRTH) ; centre de référence des maladies hémorragiques constitutionnelles (CRMH) hors maladie de von Willebrand ; Groupement hospitalier Est ; Hôpital cardiologique, 69000 Bron, France
| | - Sandrine Meunier
- Service hémostase clinique ; centre régional de traitement des hémophiles (CRTH) ; centre de référence des maladies hémorragiques constitutionnelles (CRMH) hors maladie de von Willebrand ; Groupement hospitalier Est ; Hôpital cardiologique, 69000 Bron, France
| |
Collapse
|
26
|
Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P. Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study. BMJ Open 2018; 8:e022409. [PMID: 30049701 PMCID: PMC6067371 DOI: 10.1136/bmjopen-2018-022409] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 06/08/2018] [Accepted: 06/14/2018] [Indexed: 01/14/2023] Open
Abstract
INTRODUCTION Severe haemophilia is a rare disease characterised by spontaneous bleeding from early childhood, which may lead to various complications, especially in joints. It is nowadays possible to avoid these complications thanks to substitutive therapies for which the issue of adherence is major. The transition from adolescence to adulthood in young people with severe haemophilia is a critical period as it is associated with a high risk of lack of adherence to healthcare, which might have serious consequences on daily activities and on quality of life. METHODS AND ANALYSIS We present the protocol for a cross-sectional, observational, multicentric study to assess the differences between adolescents and young adults with severe haemophilia in France through the transition process, especially on adherence to healthcare. This study is based on a mixed methods design, with two complementary and consecutive phases, comparing data from a group of adolescents (aged 14-17 years) with those from a group of young adults (aged 20-29 years). The quantitative phase focuses on the determinants (medical, organisational, sociodemographic and social and psychosocial and behavioural factors) of adherence to healthcare (considered as a marker of the success of transition). The qualitative phase explores participants' views in more depth to explain and refine the results from the quantitative phase. Eligible patients are contacted by the various Haemophilia Treatment Centres participating in the French national registry FranceCoag. ETHICS AND DISSEMINATION The study was approved by the French Ethics Committee and by the French National Agency for Medicines and Health Products Safety (number: 2016-A01034-47). Study findings will be disseminated to the scientific and medical community in peer-reviewed journals and presented at scientific meetings. Results will be popularised to be communicated via the French association for people with haemophilia to participants and to the general public. TRIAL REGISTRATION NUMBER NCT02866526; Pre-results.
Collapse
Affiliation(s)
| | - Natacha Rosso-Delsemme
- LPCPP, Aix Marseille Unviersity, Aix-en-Provence, France
- Department of Paediatric Haematology, Children Hospital La Timone, APHM, Marseille, France
| | | | - Karine Baumstarck
- CERESS, Aix Marseille University, Marseille, France
- FranceCoag Network, Marseille, France
| | - Vanessa Milien
- Department of Paediatric Haematology, Children Hospital La Timone, APHM, Marseille, France
- FranceCoag Network, Marseille, France
| | - Laurent Ardillon
- Haemophilia Treatment Centre, University Hospital of Tours, Tours, France
| | - Sophie Bayart
- Haemophilia Treatment Centre, University Hospital of Rennes, Rennes, France
| | - Claire Berger
- Haemophilia Treatment Centre, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - Marie-Anne Bertrand
- Haemophilia Treatment Centre, University Hospital of Besançon, Besançon, France
| | | | | | - Sabine Castet
- Haemophilia Treatment Centre, University Hospital of Bordeaux, Bordeaux, France
| | - Pierre Chamouni
- Haemophilia Treatment Centre, University Hospital of Rouen, Rouen, France
| | | | | | - Dominique Desprez
- Haemophilia Treatment Centre, University Regional Hospital of Strasbourg, Strasbourg, France
| | - Céline Falaise
- Department of Paediatric Haematology, Children Hospital La Timone, APHM, Marseille, France
| | - Birgit Frotscher
- Haemophilia Treatment Centre, University Hospital of Nancy, Nancy, France
| | - Valérie Gay
- Haemophilia Treatment Centre, Hospital of Chambery, Chambery, France
| | - Jenny Goudemand
- Haemophilia Treatment Centre, University Regional Hospital of Lille, Lille, France
| | - Yves Gruel
- Haemophilia Treatment Centre, University Hospital of Tours, Tours, France
| | - Benoît Guillet
- Haemophilia Treatment Centre, University Hospital of Rennes, Rennes, France
| | - Annie Harroche
- Haemophilia Treatment Centre, Hospital Necker, Assistance Publique—Hopitaux de Paris, Paris, France
| | - Abel Hassoun
- Haemophilia Treatment Centre, Hospital of Simone Veil d’Eaubonne, Montmorency, France
| | - Yoann Huguenin
- Haemophilia Treatment Centre, University Hospital of Bordeaux, Bordeaux, France
| | - Thierry Lambert
- Haemophilia Treatment Centre, Hospital Bicêtre, Assistance Publique—Hopitaux de Paris, Paris, France
| | - Aurélien Lebreton
- Haemophilia Treatment Centre, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| | - Anne Lienhart
- Haemophilia Treatment Centre, Hospital Edouard Herriot, University Hospital of Lyon, Lyon, France
| | - Michèle Martin
- Haemophilia Treatment Centre, University Hospital of Nancy, Nancy, France
| | - Sandrine Meunier
- Haemophilia Treatment Centre, Hospital Edouard Herriot, University Hospital of Lyon, Lyon, France
| | - Fabrice Monpoux
- Haemophilia Treatment Centre, University Hospital of Nice, Nice, France
| | - Guillaume Mourey
- Haemophilia Treatment Centre, University Hospital of Besançon, Besançon, France
| | - Claude Negrier
- Haemophilia Treatment Centre, Hospital Edouard Herriot, University Hospital of Lyon, Lyon, France
| | - Philippe Nguyen
- Haemophilia Treatment Centre, University Hospital of Reims, Reims, France
| | - Placide Nyombe
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France
| | - Caroline Oudot
- Haemophilia Treatment Centre, University Hospital of Limoges, Limoges, France
| | | | - Benoît Polack
- Haemophilia Treatment Centre, University Hospital of Grenoble, Grenoble, France
| | - Anne Rafowicz
- Haemophilia Treatment Centre, Hospital of Versailles, Versailles, France
- Haemophilia Treatment Centre, Hospital Bicêtre, Assistance Publique—Hopitaux de Paris, Paris, France
| | - Antoine Rauch
- Haemophilia Treatment Centre, University Regional Hospital of Lille, Lille, France
| | - Delphine Rivaud
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France
| | - Pascale Schneider
- Haemophilia Treatment Centre, University Hospital of Rouen, Rouen, France
| | - Alexandra Spiegel
- Haemophilia Treatment Centre, University Regional Hospital of Strasbourg, Strasbourg, France
| | - Cecile Stoven
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France
| | - Brigitte Tardy
- Haemophilia Treatment Centre, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - Marc Trossaërt
- Haemophilia Treatment Centre, University Hospital of Nantes, Nantes, France
| | | | - Stéphane Vanderbecken
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France
| | - Fabienne Volot
- Haemophilia Treatment Centre, University Hospital of Dijon, Dijon, France
| | | | - Bénédicte Wibaut
- Haemophilia Treatment Centre, University Regional Hospital of Lille, Lille, France
| | - Tanguy Leroy
- CERESS, Aix Marseille University, Marseille, France
- Social Psychology Research Group (GRePS EA 4163), Lumière Lyon 2 University, Lyon, France
| | - Thomas Sannie
- French Patients' Association for People with Haemophilia (AFH), Paris, France
| | - Hervé Chambost
- Department of Paediatric Haematology, Children Hospital La Timone, APHM, Marseille, France
- FranceCoag Network, Marseille, France
| | - Pascal Auquier
- CERESS, Aix Marseille University, Marseille, France
- FranceCoag Network, Marseille, France
| |
Collapse
|
27
|
Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica 2018; 103:e181-e183. [PMID: 29472355 DOI: 10.3324/haematol.2017.185330] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Affiliation(s)
- Yesim Dargaud
- Unite d'Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France .,EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France
| | - Anne Lienhart
- Unite d'Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France
| | - Maissaa Janbain
- Tulane School of Medicine, Louisiana Center for Bleeding and Clotting Disorders, New Orleans, LA, USA
| | - Sandra Le Quellec
- Unite d'Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France.,EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France
| | - Nathalie Enjolras
- EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France
| | - Claude Negrier
- Unite d'Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France.,EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France
| |
Collapse
|
28
|
Jourdy Y, Janin A, Fretigny M, Lienhart A, Négrier C, Bozon D, Vinciguerra C. Reccurrent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization. Am J Hum Genet 2018; 102:199-206. [PMID: 29357978 DOI: 10.1016/j.ajhg.2017.12.010] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Accepted: 12/12/2017] [Indexed: 01/12/2023] Open
Abstract
Incorporation of distant intronic sequences in mature mRNA is an underappreciated cause of genetic disease. Several disease-causing pseudoexons have been found to contain repetitive elements such as Alu elements. This study describes an original pathological mechanism by which a small intronic deletion leads to Alu exonization. We identified an intronic deletion, c.2113+461_2113+473del, in the F8 intron 13, in two individuals with mild hemophilia A. In vivo and in vitro transcript analysis found an aberrant transcript, with an insertion of a 122-bp intronic fragment (c.2113_2114ins2113+477_2113+598) at the exon 13-14 junction. This out-of-frame insertion is predicted to lead to truncated protein (p.Gly705Aspfs∗37). DNA sequencing analysis found that the pseudoexon corresponds to antisense AluY element and the deletion removed a part of the poly(T)-tail from the right arm of these AluY. The heterogenous nuclear riboprotein C1/C2 (hnRNP C) is an important antisense Alu-derived cryptic exon silencer and binds to poly(T)-tracts. Disruption of the hnRNP C binding site in AluY T-tract by mutagenesis or hnRNP C knockdown using siRNA in HeLa cells reproduced the effect of c.2113+461_2113+473del. The screening of 114 unrelated families with mild hemophilia A in whom no genetic event was previously identified found a deletion in the poly(T)-tail of AluY in intron 13 in 54% of case subjects (n = 61/114). In conclusion, this study describes a deletion leading to Alu exonization found in 6.1% of families with mild hemophila A in France.
Collapse
Affiliation(s)
- Yohann Jourdy
- Service d'hématologie biologique, Centre de Biologie et Pathologie Est, Bron (69500) Hospices Civils de Lyon, France; EA 4609 Hémostase et cancer, Lyon (69008), Université Claude Bernard Lyon 1, Univ Lyon, France.
| | - Alexandre Janin
- Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Bron (69500), Hospices Civils de Lyon, France; Institut NeuroMyoGène, Université Claude Bernard Lyon 1, Univ Lyon, France, CNRS UMR 5510, Villeurbanne (69100), France; INSERM U1217, Villeurbanne, France
| | - Mathilde Fretigny
- Service d'hématologie biologique, Centre de Biologie et Pathologie Est, Bron (69500) Hospices Civils de Lyon, France
| | - Anne Lienhart
- Unité d'hémostase clinique, Hôpital Cardiologique Louis Pradel, Bron (69500), Hospices Civils de Lyon, France
| | - Claude Négrier
- Service d'hématologie biologique, Centre de Biologie et Pathologie Est, Bron (69500) Hospices Civils de Lyon, France; EA 4609 Hémostase et cancer, Lyon (69008), Université Claude Bernard Lyon 1, Univ Lyon, France; Unité d'hémostase clinique, Hôpital Cardiologique Louis Pradel, Bron (69500), Hospices Civils de Lyon, France
| | - Dominique Bozon
- Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Bron (69500), Hospices Civils de Lyon, France
| | - Christine Vinciguerra
- Service d'hématologie biologique, Centre de Biologie et Pathologie Est, Bron (69500) Hospices Civils de Lyon, France; EA 4609 Hémostase et cancer, Lyon (69008), Université Claude Bernard Lyon 1, Univ Lyon, France
| |
Collapse
|
29
|
Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López‐Fernández MF, Mahlangu J, Pabinger I, Li Y, Wolko D, Voigt C, Jacobs I, Santagostino E. Efficacy and safety of long‐acting recombinant fusion protein linking factor
IX
with albumin in haemophilia B patients undergoing surgery. Haemophilia 2016; 22:e259-66. [DOI: 10.1111/hae.12972] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/07/2016] [Indexed: 01/05/2023]
Affiliation(s)
- C. Négrier
- Centre Régional de Traitement de l'Hémophilie (CRTH)/Unite d'Hemostase Clinique Hôpital Cardiologique Louis Pradel University Lyon I Lyon France
| | | | | | - A. Lienhart
- Centre Régional de Traitement de l'Hémophilie (CRTH)/Unite d'Hemostase Clinique Hôpital Cardiologique Louis Pradel University Lyon I Lyon France
| | | | - J. Mahlangu
- Haemophilia Clinic Comprehensive Care Centre Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences University of the Witwatersrand Johannesburg South Africa
- NHLS South Africa Johannesburg South Africa
| | - I. Pabinger
- Clinical Division of Haematology and Haemostaseology Medical Clinic I Medical University Vienna Vienna Austria
| | - Y. Li
- Clinical Research and Development CSL Behring King of Prussia PA USA
| | - D. Wolko
- Clinical Research and Development CSL Behring King of Prussia PA USA
| | - C. Voigt
- Clinical Research and Development CSL Behring King of Prussia PA USA
| | - I. Jacobs
- Clinical Research and Development CSL Behring King of Prussia PA USA
| | - E. Santagostino
- A. Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca' Granda Foundation Maggiore Hospital Policlinico Milan Italy
| |
Collapse
|
30
|
Lienhart A, Meunier S. [Diagnostic strategy in the face of a coagulation abnormality]. Rev Prat 2015; 65:534. [PMID: 26058206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
31
|
Lienhart A, Meunier S. [Hemorrhagic syndrome with hematologic origin]. Rev Prat 2015; 65:545-553. [PMID: 26058209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
32
|
|
33
|
Lienhart A. Respekt als Basis für eine gute Unternehmenskultur. Z Herz- Thorax- Gefäßchir 2014. [DOI: 10.1007/s00398-014-1089-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
34
|
Trossaert M, Lienhart A, Nougier C, Fretigny M, Sigaud M, Meunier S, Fouassier M, Ternisien C, Negrier C, Dargaud Y. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements. Haemophilia 2014; 20:550-8. [DOI: 10.1111/hae.12381] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/27/2013] [Indexed: 11/28/2022]
Affiliation(s)
- M. Trossaert
- Centre Regional du Traitement de l'Hemophilie; CHU de Nantes; Nantes France
| | - A. Lienhart
- Unite d'Hemostase Clinique; CHU de Lyon; Lyon France
| | - C. Nougier
- Laboratoire d'Hemostase; CHU de Lyon; Lyon France
| | - M. Fretigny
- Laboratoire d'Hemostase; CHU de Lyon; Lyon France
| | - M. Sigaud
- Centre Regional du Traitement de l'Hemophilie; CHU de Nantes; Nantes France
| | - S. Meunier
- Unite d'Hemostase Clinique; CHU de Lyon; Lyon France
| | - M. Fouassier
- Centre Regional du Traitement de l'Hemophilie; CHU de Nantes; Nantes France
| | - C. Ternisien
- Centre Regional du Traitement de l'Hemophilie; CHU de Nantes; Nantes France
| | - C. Negrier
- Unite d'Hemostase Clinique; CHU de Lyon; Lyon France
- EA 4174 Unite de Recherche sur l'Hemophilie; Universite Lyon 1; Lyon France
| | - Y. Dargaud
- Unite d'Hemostase Clinique; CHU de Lyon; Lyon France
- EA 4174 Unite de Recherche sur l'Hemophilie; Universite Lyon 1; Lyon France
| |
Collapse
|
35
|
Puybasset L, Bazin JE, Beloucif S, Bizouarn P, Crozier S, Devalois B, Eon B, Fieux F, Gisquet E, Guibet-Lafaye C, Kentish N, Lienhart A, Nicolas-Robin A, Otero Lopez M, Pelluchon C, Roussin F, Beydon L. Critical appraisal of organ procurement under Maastricht 3 condition. ACTA ACUST UNITED AC 2014; 33:120-7. [PMID: 24406262 DOI: 10.1016/j.annfar.2013.11.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The ethics committee of the French Society of Anesthesia and Intensive Care (Sfar) has been requested by the French Biomedical Agency to consider the issue of organ donation in patients after the decision to withdraw life-supportive therapies has been taken. This type of organ donation is performed in the USA, Canada, the United Kingdom, the Netherlands and Belgium. The three former countries have published recommendations formalizing procedures and operations. The French Society of Anesthesia and Intensive Care (Société française d'anesthésie et de reanimation [Sfar]) ethics committee has considered this issue and envisioned the different aspects of the whole process. Consequently, it sounded a note of caution regarding the applicability of this type of organ procurement in unselected patients following a decision to withdraw life-supportive therapies. According to French regulations concerning organ procurement in brain-dead patients, the committee stresses the need to restrict this specific way of procurement to severely brain-injured patients, once confirmatory investigations predicting a catastrophic prognosis have been performed. This suggests that the nature of the confirmatory investigation required should be formalized by the French Biomedical Agency on behalf of the French parliamentarians, which should help preserve population trust regarding organ procurement and provide a framework for medical decision. This text has been endorsed by the Sfar.
Collapse
Affiliation(s)
- L Puybasset
- Unité de neuro-anesthésie-réanimation, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - J-E Bazin
- Département d'anesthésie-réanimation, Hôtel-Dieu, boulevard Léon-Malfreyt, BP 69, 63003 Clermont-Ferrand cedex, France
| | - S Beloucif
- Service d'anesthésie-réanimation, hôpital Avicenne, 125, rue de Stalingrad, 93009 Bobigny cedex, France
| | - P Bizouarn
- Département-service d'anesthésie-réanimation, hôpital Laënnec, CHU de Nantes, boulevard Jacques-Monod, BP 1005, 44093 Nantes cedex 1, France
| | - S Crozier
- Service de neurologie, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - B Devalois
- Service de médecine palliative, centre hospitalier René-Dubos, 6, avenue de l'Île-de-France, 95300 Pontoise, France
| | - B Eon
- Département d'anesthésie-réanimation, hôpital Sainte-Marguerite, BP 29, 13274 Marseille cedex 9, France
| | - F Fieux
- Département d'anesthésie-réanimation, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75745 Paris cedex 10, France
| | - E Gisquet
- Centre de sociologie des organisations, 19, rue Amélie, 75007 Paris, France
| | - C Guibet-Lafaye
- Centre Maurice-Halbwachs-CNRS, 48, boulevard Jourdan, 75014 Paris, France
| | - N Kentish
- Groupe de recherche FAMIREA, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75745 Paris cedex 10, France
| | - A Lienhart
- Département d'anesthésie-réanimation, hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France
| | - A Nicolas-Robin
- Département d'anesthésie-réanimation, hôpital de la Pitié-Salpêtrière, boulevard de l'Hôpital, 75013 Paris, France
| | - M Otero Lopez
- Département d'anesthésie-réanimation, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75908 Paris cedex 15, France
| | - C Pelluchon
- Département de philosophie, université de Poitiers, 36, rue de la Chaîne, 86022 Poitiers, France
| | - F Roussin
- Département d'anesthésie-réanimation, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75745 Paris cedex 10, France
| | - L Beydon
- Pôle d'anesthésie-réanimation, centre hospitalier universitaire, 4, rue Larrey, 49033 Angers cedex 01, France. lbeydon.angers.@invivo.edu
| | | |
Collapse
|
36
|
Négrier C, Lienhart A, Numerof R, Stephens D, Wong WY, Baghaei F, Yee TT. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia 2013; 19:e143-50. [DOI: 10.1111/hae.12080] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/22/2012] [Indexed: 11/29/2022]
Affiliation(s)
| | | | - R. Numerof
- Baxter Healthcare Corporation; Westlake Village; CA; USA
| | - D. Stephens
- Baxter Healthcare Corporation; Westlake Village; CA; USA
| | - W. Y. Wong
- Baxter Healthcare Corporation; Westlake Village; CA; USA
| | - F. Baghaei
- Sahlgrenska University Hospital; Gothenburg; Sweden
| | | |
Collapse
|
37
|
Falzone E, Auroy Y, Hoffmann C, Sandid I, Carlier M, Benhamou D, Andreu G, Lienhart A. Erreurs de destinataire de concentrés de globules rouges : méthode d’analyse à partir de déclarations d’incidents de la chaîne transfusionnelle en 2009. Transfus Clin Biol 2012; 19:338-44. [DOI: 10.1016/j.tracli.2012.06.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2012] [Accepted: 06/16/2012] [Indexed: 11/28/2022]
|
38
|
Chevalier Y, Dargaud Y, Lienhart A, Chamouard V, Negrier C. Seventy-two total knee arthroplasties performed in patients with haemophilia using continuous infusion. Vox Sang 2012; 104:135-43. [DOI: 10.1111/j.1423-0410.2012.01653.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
39
|
Falzone É, Auroy Y, Hoffmann C, Sandid I, Carlier M, Benhamou D, Andreu G, Lienhart A. [Transfusion serious adverse events and root cause analysis]. Transfus Clin Biol 2012; 19:216-7. [PMID: 22999632 DOI: 10.1016/j.tracli.2012.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2012] [Accepted: 07/21/2012] [Indexed: 10/27/2022]
Affiliation(s)
- É Falzone
- Anesthésie-réanimation, hôpital d'instruction des armées du Val-de-Grâce, 74, boulevard de Port-Royal, 75230 Paris 05, France
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Beydon L, Ecoffey C, Lienhart A, Puybasset L. Circoncision chez l’enfant : une simple question d’organisation des soins ou un enjeu éthique ? ACTA ACUST UNITED AC 2012; 31:442-6. [DOI: 10.1016/j.annfar.2012.01.038] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2011] [Accepted: 01/17/2012] [Indexed: 10/28/2022]
|
41
|
|
42
|
Lienhart A. [Citation errors: Uplavici (for Hlava) and William the Silent (for Jules Verne and Mignet)]. Ann Fr Anesth Reanim 2011; 30:429-431. [PMID: 21481560 DOI: 10.1016/j.annfar.2011.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2011] [Accepted: 02/22/2011] [Indexed: 05/30/2023]
Abstract
A certain 'O Uplavici' was cited for more than fifty years, although he had never existed. This error probably came from a misinterpretation of the Czech language, in which the real author's name--Hlava--can mean 'Title'. It was finally recognized, which was not the case for the author of the sentence: 'I have no need of hope to take action, nor of success to persevere', it is still regularly attributed in France to William I, Prince of Orange, called the Silent. It is a mistake, and no serious reference certifies that an historical figure would have pronounced this sentence. It was written by the historian Mignet in 1841, to describe the character of William III, Prince of Orange and King of England. It was then used in 1875 by Jules Verne, to describe a character in 'The Mysterious Island'.
Collapse
Affiliation(s)
- A Lienhart
- Département d'anesthésie-réanimation, hôpital Saint-Antoine, université Pierre-et-Marie-Curie, 184 rue du Faubourg-Saint-Antoine, Paris cedex 12, France.
| |
Collapse
|
43
|
Nougier C, Sobas F, Nguyen TK, Carage ML, Lienhart A, Négrier C. Analytic variability due to change of deficient plasma vials: application to one-stage clotting factor VIII assay. Blood Coagul Fibrinolysis 2011; 22:151-4. [DOI: 10.1097/mbc.0b013e328343300e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Lienhart A. [Confidentiality: from rules to medical practice]. Ann Fr Anesth Reanim 2010; 29:832-851. [PMID: 21067887 DOI: 10.1016/j.annfar.2010.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Affiliation(s)
- A Lienhart
- Département d’anesthésie-réanimation, Hôpital Saint-Antoine et Université Pierre et Marie Curie, 184, Faubourg Saint-Antoine, 75571 Paris cedex 12, France.
| |
Collapse
|
45
|
Sobas F, Bellisario A, Tsiamyrtzis P, Lienhart A, Nougier C, Négrier C. Bayesian logic in statistical test control: application to coagulation factor VIII assay. Blood Coagul Fibrinolysis 2010; 21:289-95. [PMID: 20093930 DOI: 10.1097/mbc.0b013e328335d04d] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Coagulation factor VIII was assayed around the critical concentration of 80 U/dl, which is optimal for postoperative haemostasis in haemophiliac patients, in order to assess the use of Bayesian logic in interpreting internal quality control results during a change of reagent or control batch. A mathematical model based on Bayesian inference, requiring no preliminary control-plan phase, was compared with a classical approach, which necessarily involves performing a preliminary phase. Tsiamyrtzis and Hawkins' Bayesian model proved applicable to rapid statistical control of factor VIII assay, detecting shift at least as efficiently as classical approaches, which depend on running the kind of costly and controversial preliminary control phase recommended by Shewhart.
Collapse
Affiliation(s)
- Frédéric Sobas
- Haemostasis Laboratory, Edouard Herriot Hospital, Lyon, France.
| | | | | | | | | | | |
Collapse
|
46
|
Aouba A, De Saint Maurice G, Pavillon G, Auroy Y, Benhamou D, Lienhart A, Jougla E. Mise au point d’une méthodologie de suivi annuel des décès en rapport avec l’anesthésie. Rev Epidemiol Sante Publique 2010. [DOI: 10.1016/j.respe.2010.02.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
47
|
Bretonnière C, Capellier G, Cariou A, Eon B, Jars-Guincestre MC, Kuteifan K, Leone M, Lienhart A, Mertes PM, Piriou V, Verheyde I. Revues de morbimortalité (RMM) en réanimation : guide méthodologique. ACTA ACUST UNITED AC 2010; 29:259-63. [DOI: 10.1016/j.annfar.2010.03.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Dargaud Y, Béguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2009; 93:475-80. [PMID: 15735797 DOI: 10.1160/th04-10-0706] [Citation(s) in RCA: 235] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
In haemophilia patients, a relationship is usually observed between the clinical expression of the disease and plasmatic factor VIII/factor IX (FVIII/FIX) activity. However, it is known from clinical experience, that some haemophilia patients, despite similar FVIII/FIX plasma levels, could exhibit different bleeding phenotype. After determining preanalytical test conditions, we evaluated the thrombin generation capacity from haemophilia plasma samples in various conditions and the potential usefulness of thrombin generation test (TGT) in haemophilia patients. In a series of 46 haemophilia patients (34 haemophilia A and 12 haemophilia B patients), we found a significant correlation between plasmatic FVIII/FIX levels and endogenous thrombin potential (ETP), peak and time to peak obtained by thrombin generation measurement. In addition, a correlation was found between severe clinical bleeding phenotype and ETP. Our results suggest that TGT could be a promising tool to evaluate haemostasis capacity in patients with haemophilia. Our ex vivo results, obtained 24 hours after FVIII concentrate administration, showed that in patients presenting similar plasmatic FVIIII levels, thrombin generation capacity may be significantly different. These results suggest that in patients with haemophilia, TGT could be useful for individually tailoring prophylactic regimens as well as for adapting clotting factors infusions in surgical situations, in addition to FVIII/FIX plasma clotting activities.
Collapse
Affiliation(s)
- Yesim Dargaud
- Laboratoire d'Hemostase, Hopital Edouard Herriot, Lyon, France.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Auroy Y, Benhamou D, Péquignot F, Bovet M, Jougla E, Lienhart A. Mortality related to anaesthesia in France: analysis of deaths related to airway complications. Anaesthesia 2009; 64:366-70. [PMID: 19317699 DOI: 10.1111/j.1365-2044.2008.05792.x] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Death certificates from the French national mortality database for the calendar year 1999 were reviewed to analyse cases in which airway complications had contributed to peri-operative death. Respiratory deaths (and comas) found in a previous national 1978-82 French survey (1:7960; 95% CI 1:12,700 to 1:5400) were compared with the death rate found in the present one: 1:48,200 (95% CI 1:140,000 to 1:27,500). In 1999, deaths associated with failure of the breathing circuit and equipment were no longer encountered and no death was found to be related to undetected hypoxia in the recovery unit. Deaths related to difficult intubation also occurred at a lower rate than in the previous report (1:46,000; 95% CI 1:386,000 to 1:13,000) in 1978-82 vs 1:176,000 (95% CI 1:714,000 to 1:46,000) in 1999, a fourfold reduction. In most cases, there were both inadequate practice and systems failure (inappropriate communication between staff, inadequate supervision, poor organisation). This large French survey shows that deaths associated with respiratory complications during anaesthesia have been strikingly reduced during this 15-year period.
Collapse
Affiliation(s)
- Y Auroy
- Department of Anaesthesia, Hôpital d'Instruction des Armées Percy, Paris, France
| | | | | | | | | | | |
Collapse
|
50
|
Lienhart A. [Autopsy of a common error: the introduction of curare in Europe by W. Raleigh]. ACTA ACUST UNITED AC 2009; 28:332-8. [PMID: 19356891 DOI: 10.1016/j.annfar.2009.02.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2008] [Accepted: 02/19/2009] [Indexed: 10/20/2022]
Abstract
One of the most erroneous and repeated assertion in the history of pharmacology for anaesthetists is to say that "the curare was introduced in Europe by Sir Walter Raleigh under the name of ourari". On the contrary, the names to be reminded are: Lawrence Keymis for the first citation of the word ourari, José Gumilla for the word curare and the description of its effects, Charles-Marie de La Condamine for the import of the first known samples. The mistake was initiated by Alexander von Humboldt and developed by the physiologist Münter, a student of Johannes Müller, quoted by Claude Bernard. The repetition of this error was facilitated by the world diffusion of Claude Bernard's work.
Collapse
Affiliation(s)
- A Lienhart
- Service d'anesthésie-réanimation, hôpital Saint-Antoine, université Pierre-et-Marie-Curie, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
| |
Collapse
|